26169964
2015 Oct 1
Because of its heterogeneity, lack of prognostic markers, tumor-escape mechanisms, and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Gro√ü and colleagues characterize a rodent model that might help identify novel drugs for combinatorial sorafenib-based therapies for HCC.

